62 results
8-K
EX-99.1
VANI
Vivani Medical Inc
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
investigation of the safety, tolerability, and full pharmacokinetic profile of NPM-119 in patients with type 2 diabetes. Vivani is also preparing to submit
8-K
EX-10.2
n8h ycquuy23vp
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-10.1
qvh6l51 455r60t7
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-99.1
pnrl4m4b mkqu
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
twp4vvj9pe1pk1ex
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-3.2
yzdwh2dwdwr68x
10 Jul 23
Material Modifications to Rights of Security Holders
4:04pm
8-K
EX-99.2
mmgnchdl
15 May 23
Results of Operations and Financial Condition
6:49am
DEFR14A
7cr7agxkzpcao2rv8bd
1 May 23
Revised proxy
4:49pm
8-K
EX-10.1
1vnlg67n shze
28 Nov 22
Entry into a Material Definitive Agreement
5:29pm
8-K
EX-99.1
dpwezwb3z41dojok8en
14 Nov 22
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
4:14pm